

Search

EN

Back

Changshan Pharma Stock Drops 4.4% Despite FDA Drug Approval

Back

Stock NewsThemesChangshan Pharma Stock Drops 4.4% Despite FDA Drug Approval

Changshan Pharma Stock Drops 4.4% Despite FDA Drug Approval

Edgen Stock·Jan 09 2026, 14:25

Share to

Share to

Copy link

source:

[1] Changshan Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection Receives US Drug Registration Approval

Recommend

Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder ReturnsNov 28 2025, 10:17 US-China AI Rivalry Enters New Phase Focused on Compute Power and CybersecurityNov 28 2025, 10:17 Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder ReturnsNov 28 2025, 10:17

Hot News

Virtual Reality (VR)Xiaomi EV Unit Hits 25.5% Margin, Powering Profit ShiftJan 12 2026, 20:35

US Seizes Russian Tanker, Escalating Direct Pressure on PutinJan 12 2026, 09:02

Nancy PelosiUS-China AI Rivalry Enters New Phase Focused on Compute Power and CybersecurityJan 12 2026, 08:56

Societe Generale Forecasts Fed Rate Cuts Driving Treasury Yields Lower Through 2026Dec 01 2025, 07:07